Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study

izokibep (ABY-035) - Affibody

https://acrabstracts.org/abstract/efficacy-and-safety-of-izokibep-a-novel-il-17a-inhibitor-in-patients-with-active-psoriatic-arthritis-week-52-results-from-a-randomized-double-blind-placebo-controlled-multicenter-phase-2b-3-stu/

Philip Mease1; Frank Behrens2; Alan Kivitz3; Edit Drescher4; Piotr Klimiuk5; Howard Sofen6; Nehad Soloman7; Shephard Mpofu8; Fredrik Frejd9; Peter Taylor10

Oct 14, 2025